Identification of androgen-coregulated protein networks from the microsomes of human prostate cancer cells by Wright, Michael E et al.
Genome Biology 2003, 5:R4
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
Open Access 2003 Wright et al. Volume 5, Issue 1, Article R4 Research
Identification of androgen-coregulated protein networks from the 
microsomes of human prostate cancer cells
Michael E Wright*, Jimmy Eng*, James Sherman*, David M Hockenbery†, 
Peter S Nelson†, Timothy Galitski* and Ruedi Aebersold*
Addresses: *Institute for Systems Biology, Seattle, WA 98103, USA. †Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. 
Correspondence: Ruedi Aebersold. E-mail: raebersold@systemsbiology.org
© 2003 Wright et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.
Identification of androgen-coregulated protein networks from the microsomes of human prostate cancer cells Androgens play a critical role in the development of prostate cancer-dysregulation of androgen-regulated growth pathways can led to hor- mone-refractory prostate cancer. A comprehensive understanding of androgen-regulated cellular processes has not been achieved to date.  To this end, we have applied a large-scale proteomic approach to define cellular processes that are responsive to androgen treatment in  LNCaP prostate cancer cells.
Abstract
Background: Androgens play a critical role in the development of prostate cancer-dysregulation
of androgen-regulated growth pathways can led to hormone-refractory prostate cancer. A
comprehensive understanding of androgen-regulated cellular processes has not been achieved to
date. To this end, we have applied a large-scale proteomic approach to define cellular processes
that are responsive to androgen treatment in LNCaP prostate cancer cells.
Results: Using isotope-coded affinity tags and mass spectrometry we identified and quantified the
relative abundance levels of 1,064 proteins and found that distinct cellular processes were
coregulated by androgen while others were essentially unaffected. Subsequent pharmacological
perturbation of the cellular process for energy generation confirmed that androgen starvation had
a profound effect on this pathway.
Conclusions: Our results provide evidence for the role of androgenic hormones in coordinating
the expression of critical components involved in distinct cellular processes and further establish a
foundation for the comprehensive reconstruction of androgen-regulated protein networks and
pathways in prostate cancer cells.
Background
Androgens are critical for the growth of normal and diseased
prostate epithelium [1]. Androgenic ligands bind and activate
the androgen receptor (AR) leading to the induction of pros-
tate-specific genes associated with cell growth and the differ-
entiated prostate epithelial phenotype [2]. The biological
impact that androgens have on prostate epithelial cell func-
tion is underscored by the fact that androgen deprivation
therapy is an established therapeutic regime in the treatment
of advanced prostate cancer (PCa) [3]. However, PCa that
emerges after androgen deprivation therapy routinely re-acti-
vates the androgen-response pathway during the
development of hormone refractory PCa [4-9]. Large-scale
transcript profiling studies have been initiated in order to
identify androgen-regulated genes in human PCa cell lines
with the intent that these targets will elucidate the pathways
that result in hormone refractory PCa growth [10-13]. How-
ever, transcript-expression profiles do not always reflect
changes that occur at the level of the protein [14]. As proteins
are the biological effectors of cell function, an assessment of
their quantity and activation state provides a more informa-
tive description of a cellular phenotype. Therefore, we have
initiated a large-scale quantitative proteomic analysis to sys-
tematically identify and quantify androgen-mediated protein
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abundance changes in the human LNCaP prostate cancer cell
line using the isotope-coded affinity tags (ICAT) and mass
spectrometry [15,16]. This investigation represents a first-
step towards mapping a protein network regulated by andro-
gens in neoplastic prostate epithelium.
Results and discussion
Identification and quantification of microsomal 
proteins
One of our primary research goals is to obtain a global view of
androgen-mediated protein abundance changes in human
prostate cancer cells in response to androgens. We have initi-
ated studies to systematically quantify all androgen-mediated
protein abundance changes that occur within the nuclear,
membranous and cytosolic fractions of human prostate can-
cer cells using the ICAT reagent method. In this article we
focused on characterizing the protein abundance changes
found within the membranous fraction of LNCaP cells using a
crude microsomal protein preparation methodology previ-
ously employed [16]. Total protein isolated from the micro-
somes of androgen-depleted (AD  cells) and androgen-
stimulated (AS cells, 10 nM R1881 for 72 hrs) LNCaP cells
were subjected to proteomic analysis using the ICAT method.
The ICAT-labeled peptide mixture (AD  cells, d0-reagent
(light ICAT isotope reagent); AS  cells, d8-reagent (heavy
ICAT isotope reagent)) was subjected to three-dimensional
liquid chromatography and analyzed by tandem mass spec-
trometry (MS/MS), which resulted in the identification and
quantification of 1,064 proteins (Figure 1a and panel 1, pages
1-58 in Additional data file 1) [15,16]. A plot of the natural log
of the d8-heavy/d0-light abundance ratios of the identified
proteins revealed that 98.4% (1,047/1,064 proteins) changed
less than four-fold and 81.2% (864/1,064) changed less than
two-fold in response to androgen exposure (Figure 1a and
panel 1, pages 1-58 in Additional data file 1).
Androgenic hormones have been reported to regulate the
expression of a large number of genes in the prostate [17].
One of the best-characterized androgen responsive targets is
prostate specific antigen (PSA), a secreted serine protease
that is commonly used to detect early stage PCa in men [17].
The PSA polypeptide sequence is predicted to generate six
cysteine-containing tryptic peptides, all of which were identi-
fied and quantified by the ICAT method (Figure 1b,c). PSA
was easily detectable in the microsomes of AS cells (Figure
1d). We extended the orthogonal verification of protein abun-
dance ratios determined by quantitative mass spectrometry
by subjecting a small group of proteins to semi-quantitative
western blot analysis (Figure 1f-l). A four-fold increase in AS
cell PSA expression was determined by the ICAT method
(Figure 1e and panel 2, page 59 in Additional data file 1); a
finding that was confirmed by Western analysis. An approxi-
mately eight-fold increase in the expression of the known
androgen-regulated transmembrane serine protease 2
(TMPRSS2) level in AS  cells was measured by the ICAT
method, and Western analysis supported this result (Figure
1f) [18,19]. Androgens are known to activate the lipogenic
pathway in PCa cells [20-22]. The ICAT method demon-
strated that fatty acid synthase (FAS) and low-density lipo-
protein receptor (LDLR) proteins were increased by
approximately three- and approximately 1.8-fold, respec-
tively in AS cells (Figure 1g,h). β-catenin, a component of cel-
lular adherens junctions [23] that also functions as a co-
activator of AR mediated transcription [24-26], was
increased approximately 1.3-fold in AS cells (Figure 1i), while
the heat shock chaperonin 60 protein (HSP60), was
increased approximately 1.7-fold in AD cells, as measured by
the ICAT method (Figure 1j). The abundance ratios for these
proteins were calculated from the assessments of at least
three independent peptide quantifications, providing an
opportunity to estimate the amount of error in the quantita-
tive measurement (panel 2, page 59 in Additional data file 1).
We also confirmed protein quantifications that were derived
from single ICAT peptide ratios. For example, the human
sterile 20 serine/threonine protein kinase 3 (mst-3) [27] and
the Type II transmembrane protein Fas ligand (FasL) [28]
were quantified based upon single ICAT peptide ratios (panel
3, page 60 in Additional data file 1). The ICAT method meas-
ured an approximately 1.8-fold increase in mst-3 levels in AS
cells, while FasL levels were relatively unchanged between AD
and AS cells, which was verified by immunoblot analysis (Fig-
ure 1k,l, respectively). While it is preferable to assess multiple
ICAT-labeled peptides corresponding to a particular protein
for optimal quantitative accuracy, these validation experi-
ments demonstrate the validity of protein quantifications
determined by single ICAT measurements.
Assignment of proteins into cellular process categories
Interpretation of large-scale cDNA microarray and proteomic
analyses has traditionally been plagued by the inability to
organize the vast amounts of data into a meaningful biologi-
cal framework from which new hypotheses can be developed
and tested experimentally [29]. Therefore, we sought to gain
a deeper understanding of the functional pathways that were
represented in the 1,064-protein dataset. Proteins were
assigned to one or several cellular process categories (of a
possible 44 categories) based upon their annotation at the
Incyte Human Proteome Database [30]. These cellular proc-
ess categories are a reflection of the biological process ontol-
ogy adopted by the Gene Ontology hierarchical classification
system [31,32]. Non-annotated proteins were assigned to the
cellular process referred to as 'unknown process', which
allowed for the assignment of all 1,064 proteins to one or mul-
tiple cellular process categories (Figure 2 and panel 4, pages
61-238 in Additional data file 1). The unknown process cate-
gory contained approximately 19% of the identified proteins
(Figure 2), which is consistent with the observation that a sig-
nificant fraction of genes encoded in the human genome have
no defined function [33]. The category of 'signal transduction'
contained the second largest number of identified proteins at
approximately 9%, while cellular processes associated withhttp://genomebiology.com/2003/5/1/R4 Genome Biology 2003,     Volume 5, Issue 1, Article R4       Wright et al. R4.3
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cellular growth, ion transport and metabolism represented
approximately 33% of all identified proteins (for example,
protein synthesis, 5.38%; energy generation, 4.68%; vesicular
transport, 4.30%; protein modification, 4.24%; lipid metabo-
lism, 3.99%; small molecule transport, 3.86%; nucleotide
metabolism, 3.48%; carbohydrate metabolism, 3.42%). Of 45
defined cellular process categories, 42 contained at least one
protein observed in this experiment, while no proteins were
assigned to the categories of 'asymmetric cell division', 'mito-
chondrial transcription' and 'Pol I transcription' (Figure 2).
Identification of androgen-sensitive and androgen-
insensitive cellular processes
Assignment of the 1,064 proteins to a specific cellular process
provided a unique opportunity to determine whether certain
cellular processes are under the control of androgens in
LNCaP cells. For example, androgens are known to regulate
lipid metabolism in PCa cells [20-22], and a group of proteins
in the 'lipid metabolism' cellular process contained ICAT
ratios (d0:d8) that were consistent with the androgen-medi-
ated stimulation of this cellular process (panel 5, pages 239-
242 in Additional data file 1). This led us to investigate the
distribution among cellular process categories of proteins
showing expression change (up or down) greater than a pre-
determined threshold. For example, among the 1,064 pro-
teins detected, 350 (33%) showed an androgen-response
change greater than or equal to 1.6-fold (panel 6, page 243 in
Additional data file 1). If these 350 proteins were distributed
randomly among the cellular process categories, it would be
expected that about one third of the proteins in each category
would show expression change ≥1.6. Alternatively, there may
be categories in which androgen-responsive proteins are
Identified proteins derived from the microsomes of AD and AS cells ordered by ratios of abundance Figure 1
Identified proteins derived from the microsomes of AD and AS cells ordered by ratios of abundance. (a) Plot of the natural log d8/d0 ratio of the total 
number of ICAT reagent-labeled proteins derived from microsomes of 72 h AD (d0, light ICAT isotope reagent) and AS (10 nM R1881(methyltrienolone)) 
(d8, heavy ICAT isotope reagent) cells. Red and green represent androgen-induced and repressed protein abundance changes. A total of 1,064 proteins 
were identified and quantified (detailed in Materials and methods). (A list of all proteins is contained in panel 1 (pages 1-58) in Additional data file 1.) (b) 
PSA polypeptide sequence. Bold italics denote tryptic, cysteine-containing peptides. (c) Observed ICAT reagent-labeled PSA peptides. The number after 
each peptide sequence denotes the number of times that a peptide was identified. (d) PSA expression in the microsomes of AS cells. (e-l) Comparative 
immunoblot analysis of AD (d0) and AS (d8) microsomal extracts probed with antibodies to PSA, TMPRS22, FAS, LDLR, β-catenin, HSP60, MST-3 and FasL, 
respectively. Mass spectrometric d0/d8 ratios as displayed by the XPRESS quantification software [16] are shown below each blot. The asterisk denotes 
the cleaved processed form of the TMPRS22 protease [19].
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over-represented, thus identifying androgen-responsive cel-
lular processes. Also, there may be categories in which
androgen-responsive proteins are under-represented, thus
identifying cellular processes likely to be androgen-insensi-
tive.
Using the hypergeometric distribution [34], we calculated p-
values for the observed number of proteins that changed by
more than a specified ratio threshold compared with the
number expected at random for each cellular process cate-
gory. In Table 1, a low p-value indicates that the observed
number of proteins with changes ≥1.6 deviates significantly
from the number expected at random (panel 6, page 243 in
Additional data file 1; see also panel 8 on page 244 and panel
9 on page 245, for p-values for ICAT ratio thresholds of ≥1.8
and ≥2.0, respectively). This deviation can be either greater
(over-representation) or lesser (under-representation) than
expected. Table 1 shows cellular process categories containing
Classification of microsomal proteins in prostate epithelial cells into cellular process categories Figure 2
Classification of microsomal proteins in prostate epithelial cells into cellular process categories. The 1,064 proteins identified and quantified in this study 
were assigned to one or several cellular process categories on the basis of their annotation at the Incyte Human Proteome Database [30]. Unassigned 
proteins were placed into the cellular process category referred to as 'unknown process'. The numbers in parentheses represent the total number of 
proteins assigned to that specific cellular process category.
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p-values less than 0.004. Each of these categories represents
cellular processes likely to be either androgen-responsive
(over-represented) or androgen-insensitive (under-repre-
sented). The androgen-responsive cellular processes included
'RNA splicing' (5.92 × 10-5), 'energy generation' (3.01 × 10-4),
'nucleotide metabolism' (5.20 × 10-4), 'lipid metabolism'
(2.30 × 10-3) and 'RNA processing/modification' (2.32 × 10-
3). The androgen-insensitive cellular processes included
'vesicular transport' (1.87 × 10-3) and 'protein synthesis' (3.1 ×
10-3).
Coregulated protein expression associated with energy 
and lipid metabolism
The identification of both androgen-responsive and andro-
gen-insensitive cellular processes prompted us to document
the direction (either up or down) of those proteins with
expression ratios ≥1.6 among these cellular processes. These
proteins could display either discordant or concordant pro-
tein abundance changes. Concordant increases or decreases
in protein levels would support the concept of androgen-
mediated coregulated protein expression involving specific
cellular process categories. The large number of proteins with
expression ratios ≥1.6 provided the opportunity to sort these
proteins based upon their expression ratio (d0/d8 and d8/
d0) and determine the direction of change in response to
androgen (panel 9, pages 246-269 in Additional data file 1).
For example, inspection of the 'RNA splicing' cellular process
(panel 9, pages 265-269 in Additional data file 1, category 38)
revealed that 12 out of the 14 proteins containing ICAT ratios
≥1.6 were all increased in AD cells, suggesting a coordinated
coregulated protein expression pattern influencing this cellu-
lar process. To highlight the connectivity of coregulated pro-
tein expression patterns displayed among the androgen-
responsive cellular processes, we reconstructed the biochem-
ical pathways associated with the 'energy generation' and
'lipid metabolism' biochemical processes (Figure 3 and panel
10, pages 270-274 in Additional data file 1). This included the
tricarboxylic acid cycle (TCA), oxidative phosphorylation
(Oxphos), glycolysis, fatty acid β-oxidation, glycogen metab-
olism, fatty acid synthesis and cholesterol synthesis path-
ways. As previously reported [20,21], androgen stimulated
many of the enzymes (for example, FAS and citrate synthase
(CS)) involved in the anabolic processes of fatty acid and cho-
lesterol synthesis (Figure 3). Androgen also stimulated glyco-
gen catabolism [35], as both glycogen phosphorylase and
glycogen transferase increased in AS cells, suggesting that
androgens promote mobilization of glycogen stores for
energy production. However, androgen also had a repressive
effect on the catabolic pathways of glycolysis, TCA, Oxphos
and fatty acid oxidation, as these pathways were coordinately
decreased in AS  cells (Figure 3). In addition, enzymes
required for the breakdown of straight and branched-chain
fatty acids in the mitochondria and peroxisome were specifi-
cally increased in AS cells (Figure 3). This suggests that these
pathways were up-regulated to increase the synthesis of two
carbon acetyl-CoA subunits for subsequent oxidation in the
TCA cycle and the synthesis of ATP by the Oxphos pathway.
This observation is clinically relevant to PCa, since α-methyl-
acyl-CoA racemace (AMACR), the enzyme which catalyzes a
required step for the β-oxidation pathway in peroxisomes
[36], is specifically over-expressed in PCa and represents a
new molecular marker for early stage PCa [37-39]. De-repres-
sion of the α and β branched-chain fatty acid oxidation path-
ways may represent an early androgen-deregulated step in
PCa development [40]. The distinct increase in protein com-
ponents of the glycolytic, TCA, and Oxphos pathways in AD
cells also suggests that these pathways were specifically
increased to meet a metabolic demand for ATP in AD cells
(Figure 3). Interestingly, normal prostate epithelial cells are
known to accumulate and secrete large amounts of citrate
Table 1
Androgen-sensitive and androgen-insensitive cellular processes
Group Cellular process ICAT-labeled protein 
ratios ≥1.6
ICAT-labeled proteins in 
cellular process
Observed compared with 
expected
p-value
38 RNA splicing 12 14 Over 5.92E-05
18 Energy generation 38 74 Over 3.01E-04
25 Nucleotide metabolism 30 56 Over 5.20E-04
43 Vesicular transport 12 68 Under 1.87E-03
19 Lipid, fat and sterol metabolism 31 63 Over 2.30E-03
37 RNA processing/modification 25 48 Over 2.32E-03
35 Protein synthesis 17 84 Under 3.11E-03
For each cellular process category, the observed number of proteins showing an ICAT ratio ≥1.6 was compared to the number expected at random. 
Using the hypergeometric distribution, a p-value was calculated for each cellular process category from four numbers: the total number of ICAT-
reagent labeled proteins (1,064), the total number of proteins with ICAT ratios ≥1.6 (350), the number of ICAT-reagent labeled proteins in the 
cellular process category, and the number of ICAT-reagent labeled proteins in the cellular process category with a ratio ≥1.6. Cellular process 
categories showing low p-values are shown. Each of these has either an over-representation of changed proteins or an under-representation.R4.6 Genome Biology 2003,     Volume 5, Issue 1, Article R4       Wright et al. http://genomebiology.com/2003/5/1/R4
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into the lumen of the prostate [41]; citrate, a required
intermediate for the complete oxidation of glucose and fats,
has been shown to decline dramatically in PCa [42]. A meta-
bolic shift towards increased citrate oxidation has been pro-
posed to represent an early step when a pre-neoplastic cell
transforms into a malignant PCa cell [43]. Our results show
that de-repression of energy related pathways could be a nat-
ural consequence of inactivating the androgen signaling path-
way in PCa.
Chemical perturbations of energy metabolism in 
prostate cancer cells
AD cells increased the levels of proteins associated with the
'energy generation' cellular process, suggesting that these
cells were metabolically different in the context of mitochon-
drial function compared with AS  cells (Figure 3). We
o b s e r v e d  t h a t  a n d r o g e n  s t a r v a t i o n  c a u s e d  L N C a P  c e l l s  t o
adopt a distinct neuronal morphology (Figure 4a, middle
panel) when compared to steady-state (SS) or AS cells (Figure
4a, left and right panel, respectively), a finding also reported
by other investigators [44]. The cellular distribution of
mitochondria in AD cells was quite distinct as the mitochon-
dria traversed the length of the long dendritic-like processes
(Figure 4b, middle panel), whereas SS and AS cells displayed
a more perinuclear mitochondrial localization pattern (Fig-
ure 4b, left and right panels, respectively). The coordinated
increase in proteins of the 'energy generation' cellular process
in AD cells led us to hypothesize that these cells were stressed
Androgen-responsive metabolic protein network in LNCaP cells Figure 3
Androgen-responsive metabolic protein network in LNCaP cells. Specific biochemical pathways represented by the 'energy generation' and 'lipid 
metabolism' cellular processes, which included the TCA cycle, oxidative phosphorylation, glycolysis, glucogenesis, cholesterol synthesis, glycogen 
catabolism, fatty acid synthesis and fatty acid oxidation are shown to demonstrate the coordinated coregulated protein expression pattern in response to 
androgen in LNCaP cells. Black roman font represents proteins not identified using the ICAT reagent method. Black italic font represents proteins that did 
not change with androgen exposure (d0/d8 ratios > 0.62 and < 1.60). Red represents proteins whose abundance increased with androgen treatment (d0/
d8 ratios ≤0.62). Green represents proteins whose abundance decreased following androgen treatment (d0/d8 ratios ≥1.6).
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at the level of the mitochondria. To test whether AD cells had
an increased sensitivity to pharmacological agents that spe-
cifically disrupt different steps of the Oxphos pathway when
compared with AS cells, we incubated SS, AD and AS cells
with rotenone (10 µM), carbonyl cyanide m-chlorophenylhy-
drazone (CCCP) (50 µM), antimycin A (10 µg/ml) or oligomy-
cin (5 µg/ml) and determined cell viability 24 hours later
(Figure 4c). As shown in Figure 4c, a 24 h exposure to roten-
one, which specifically blocks the NADH dehydrogenase of
complex I [45] elicited a slightly higher level of cell death in
AD (38.1 ± 3.0%) cells when compared to AS (31.8 ± 2.0%)
and SS cells (27.2 ± 1.9%). CCCP, a small aliphatic agent that
uncouples electron transport and ATP production [46],
resulted in higher levels of cell death in AD cells (53.7 ± 1.9%)
when compared to AS (41.5 ± .79%) and SS cells (29.0 ±
2.9%). Antimycin, which specifically blocks complex III of the
respiratory chain between cytochrome b and cytochrome c1
[47], induced higher levels of cell death in AD cells (50.9 ±
2.4%) when compared with AS cells (31.1 ± 2.6%) or SS cells
(19.9 ± 1.1%). Lastly, oligomycin, which blocks ATP synthesis
by binding the F0F1-ATPase of complex V of the respiratory
chain [48], also induced higher levels of cell death in AD cells
(48.5 ± 1.7%) than in AS (24.1 ± 6.6%) and SS cells (15.8 ±
2.3%). These results clearly show that androgen depletion
sensitizes LNCaP cells to cell death induced by drugs that per-
turb the respiratory chain pathway. A number of plausible
explanations could explain the increased cell death response
of AD cells to mitochondrial poisons. For example, the neuro-
nal phenotype of AD cells, which resembles the neuroendo-
crine phenotype of some advanced, hormone refractory PCa
that arise after long-term androgen ablation therapy [49,50],
may utilize different carbon sources that predispose them to
activation of the cell death pathway if mitochondrial function
is compromised. Although the biochemical mechanism(s)
responsible for inducing higher levels of death in AD cells has
yet to be defined, we have established a novel relationship
between androgen and energy metabolism in LNCaP cells
that will require further scientific inquiry. Whether or not this
relationship is maintained in other androgen-dependent
prostate cancer cell lines is unknown. However, in the context
of clinical therapy for prostate carcinoma, applying tradi-
tional androgen-ablation methods in combination with drugs
that specifically target the mitochondria may increase the
therapeutic efficacy of existing treatment approaches.
Conclusions
In this article we have applied a large-scale quantitative mass
spectrometry approach to reconstruct the androgen-respon-
sive protein network in human prostate cancer cells. This
study represents the largest dataset of identified and
quantified proteins from human cells to date. Our primary
goal was to construct an androgen-regulated protein abun-
dance map from the microsomal fraction of prostate cancer
cells. Future analyses that quantify androgen-mediated pro-
tein abundance changes from the nuclear and cytoplasmic
fractions will provide a more global perspective of the andro-
gen-responsive protein networks in prostate cancer cells.
F r o m  t h e  c u r r e n t  a n a l y s i s  w e  w e r e  a b l e  t o  i d e n t i f y  b o t h
androgen-sensitive and androgen-insensitive cellular proc-
esses. Androgen-responsive cellular processes displayed a
coregulated protein expression pattern in response to andro-
gen, suggesting that these cellular processes were coordi-
nately controlled and share a common gene expression
regulatory network (for example, common transcription fac-
tor binding sites in their promoters) [51]. The androgen-
responsive proteins of the 'energy generation' cellular process
were specifically increased in AD cells, suggesting these cells
were metabolically stressed. Pharmacological perturbation
with drugs that specifically blocked mitochondrial respiration
induced higher levels of cell death in AD cells when compared
with AS cells, thus validating the utility of applying a large-
scale quantitative proteomic approach to uncover biological
differences between two cellular states. Systematic analysis of
the other androgen-responsive cellular processes may
increase our understanding of androgen and AR signaling in
the development of androgen-refractory PCa. For example,
proteins comprising the 'RNA splicing' and 'RNA processing/
modification' cellular processes were specifically increased
(panel 9, pages 262-269 in Additional data file 1, categories 37
and 38) in AD cells. Interestingly, steroid receptors can coor-
dinate transcription and splicing through their association
with specific nuclear receptor coregulatory proteins [52]. AR
may coordinate a similar activity in prostate epithelial cells,
as AR can physically interact with FLH2 [53], a tissue-specific
AR co-activator, which can bind the polypyrimidine tract
binding protein-associated splicing factor [54]. Future stud-
ies will be required to elucidate the relationship, if any,
between androgen and RNA splicing/metabolism in prostate
cancer cells, given that many cancers are associated with
abnormalities in alternative splicing [55].
We also identified several generally androgen-insensitive cel-
lular processes, including 'vesicular transport' and 'protein
synthesis'. However, androgens may still influence these
p a t h w a y s  b y  r e g u l a t i n g  t h e  e x p r e s s i o n  o f  a  f e w  c r i t i c a l
modulators. These processes may also be regulated through
alternative regulatory mechanisms that involve post-transla-
tional modifications (for example, phosphorylation and ubiq-
uitination). Future analyses will be required to substantiate
and test these hypotheses more directly. The androgen coreg-
ulated protein expression patterns described in this study are
consistent with the coregulated gene expression patterns
detected by large-scale cDNA microarray analyses [56].
Coregulated gene and protein networks may represent a
common theme for coordinating cellular processes in the cell.
Targeting and blocking the activity of specific regulators
through RNA interference or chemical inhibitors will help
uncover the biological consequences of these specific coregu-
lated cellular processes found in this analysis. Robust charac-
terization of existing cellular processes and the creation of
new cellular process categories may uncover the function ofR4.8 Genome Biology 2003,     Volume 5, Issue 1, Article R4       Wright et al. http://genomebiology.com/2003/5/1/R4
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Figure 4 (see legend on next page)
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unknown coregulated genes and proteins. Overall, utilizing a
large-scale quantitative proteomic approach via the ICAT rea-
gent method may elucidate analogous growth factor and hor-
mone responsive pathways in other model systems.
Materials and methods
Preparation of microsomal fractions, ICAT reagent 
labeling and mass spectrometric analysis
Microsomes were prepared and isolated from androgen-
depleted and androgen-stimulated LNCaP cells (109). Cells
were exposed to either phenol-red deficient RPMI 1640 (Inv-
itrogen, Carlsbad, CA) media supplemented with 10% char-
coal-stripped fetal bovine serum (androgen-depleted, AD
cells) (Hyclone Laboratories Inc., Logan, UT) or androgen-
depleted media supplemented with 10 nM R1881 (methyl-
trienolone, Perkin Elmer Life Sciences, Boston, MA) (andro-
gen-stimulated,  AS  cells) for 72 h. A total of 5.0 mg of
microsomal proteins, 2.5 mg from AD cells and 2.5 mg from
AS cells, were ICAT reagent labeled (AD, d0-ICAT reagent,
AS, d8-ICAT reagent) as previously described [16] with the
following modifications: microsomes were reduced with 5
mM tributylphosphine (TBP) for 3 h, and TBP reduced
extracts were ICAT reagent labeled for 3 h and digested with
trypsin overnight at 37°C. The 5 mg trypsin digested ICAT-
reagent labeled peptide mixture was subjected to cation
exchange, and then 53 cation-exchanged and avidin-purified
ICAT-reagent labeled fractions were analyzed by microcapil-
lary liquid chromatography electrospray ionization tandem
mass spectrometry (µLC-ESI-MS/MS) [16].
SEQUEST, INTERACT and XPRESS scoring criterion
Uninterpreted MS/MS spectra were searched against a data-
base of approximately 73,600 human sequences generated as
a subset of a non-redundant amino acid database down-
loaded from the National Cancer Institute's Advanced Bio-
medical Computing Center [57]. Tandem mass spectra were
analyzed using the SEQUEST database search software. The
database search criteria included a static modification of
cysteine residues of 503 Da (mass of cysteine plus light ICAT
reagent tag) and a variable modification of 8 Da for cysteines
(for the heavy ICAT reagent tag). Additionally, searches were
performed with no enzyme-constraint on the peptides ana-
lyzed from the sequence database. SEQUEST output was ana-
lyzed using the INTERACT program where peptides
containing the following values were considered to be correct
identifications: Xcorr > 1.5, ∆ correlation scores ≥ 0.1, Sp rank
≤ 8, singly tryptic, contain at least one cysteine residue. This
generated a list that contained 5,450 MS/MS spectra. All
peptide identifications were confirmed by manual inspection
of the data. Comparing these criteria to those generated from
the PeptideProphet software [58], 93% of the entries had a
probability of 0.99 or higher and 97% of the entries in the list
had a probability of 0.90 or higher. All d0/d8 peptide ratios
were analyzed and validated/corrected using the XPRESS
[16] quantification program. Quantitative ratios are gener-
ated by taking the ratios of the calculated heavy and light elu-
tion peak areas for ICAT-reagent labeled peptides. As we have
calculated ratios only for those ions that we have acquired and
confirmed the identification of by MS/MS, we can also quan-
tify what are termed 'singleton' peaks. This is because we
always start with a positive identification for the singleton
elution peak so the presence of a peak for the counterpart ion
is not required.
Immunoblotting, immunofluorescence and 
microscopy
Microsomal protein lysates derived from 72 h AD and AS cells
(16 µg) were subjected to immunoblot analysis using 1 µg/ml
mouse anti-PSA (Research Diagnostics Inc. RDI-PSA85abm/
RDI-PSA85abm-1), 1:1,500 dilution of rabbit anti-TMPRSS2,
1:200 dilution of rabbit anti-LDLR (Research Diagnostics
Inc.), 1 µg/ml mouse anti-MST-3 (BD Transduction Labora-
tories clone 47), 1 µg/ml mouse anti-FAS (BD Transduction
Laboratories clone 23), 2 µg/ml mouse anti-β-catenin (BD
Transduction Laboratories clone 14), 1 µg/ml mouse anti-Fas
ligand (BD Transduction Laboratories clone 13) and 0.05 µg/
ml mouse anti-Hsp-60 (Stressgen clone LK1). 72 h AD, AS
and LNCaP cells grown in phenol-red deficient RPMI 1640
containing 10% fetal bovine serum (steady-state cells, SS
cells) were labeled with the Mitotracker® Red CMXRos and
Alexa Fluor 488 phalloidin and DAPI (4',6-diamidino-2-phe-
nylindole, dihydrochloride) conjugates (Molecular Probes,
Eugene, OR) according to the manufacturers instructions
[59]. Fluorescent images were acquired on an DeltaVision
microscope (Applied Precision, Inc., Issaquah, WA) and
image stacks were deconvolved using SoftWoRx 2.5 (API). All
images were processed at the Scientific Imaging Lab, Fred
Hutchinson Cancer Research Center. Light microscope pho-
tographs of cells were imaged with Fujifilm Super HQ 35 mm
film (100 speed film) at 10X on an Olympus IX70 inverted
microscope.
Cell death assay
LNCaP cells were seeded and exposed to three growth condi-
tions for 72 hours prior to a 24 hour incubation with the res-
piratory chain inhibitors. These three growth conditions
included normal growth medium (steady-state, SS;
Respiratory chain inhibitors induce higher levels of cell death in AD cells Figure 4 (see previous page)
Respiratory chain inhibitors induce higher levels of cell death in AD cells. (a) Light photomicrographs of SS, AD and AS cells after 72 h. (b) Distribution of 
mitochondria in SS (left), AD (center) and AS (right) cells. (c) Respiratory chain inhibitors rotenone (10 µM), CCCP (50 µM), antimycin A (10 µg/ml) and 
oligomycin (5 µg/ml) induce higher levels of cell death in AD cells, as assessed by a cell counting assay after a 24 h incubation with the specified drugs. Data 
are representative of three independent experiments.R4.10 Genome Biology 2003,     Volume 5, Issue 1, Article R4       Wright et al. http://genomebiology.com/2003/5/1/R4
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androgen-depleted, AD and androgen-stimulated, AS). 72 h
AD, AS and SS cells were incubated with the respiratory chain
inhibitors rotenone (10 µM), carbonyl cyanide m-chlorophe-
nylhydrazone (CCCP) (50 µM), antimycin A (10 µg/ml), oli-
gomycin (5 µg/ml), for 24 h. Untreated cells were incubated
with vehicle (ethanol) for 24 h. SS cells were seeded at a den-
sity of 1 × 103 cells/cm2 while AD and AS cells were seeded at
a density of 3 × 103 cells/cm2 to generate equivalent cell den-
sities at the time of drug addition. Cell death was determined
using the trypan-blue dye assay [60]. At least 200 cells were
counted in triplicate for all experiments. All drugs were pur-
chased from Sigma.
Assignment of identified proteins into cellular process 
categories
All identified proteins that contained a Swiss-Prot annotation
were searched at the Incyte Human Proteome Database [30]
and assigned to one or several cellular process categories if
applicable. All remaining proteins that contained a Genbank
GenPept accession number were searched at the Incyte
Human Proteome Database and assigned to a cellular process
category if applicable. Non-annotated proteins were assigned
to the cellular process category described as 'unknown
process'.
Additional data file
An additional data file (Additional data file 1) containing all
ICAT protein quantifications and statistical analyses pertain-
ing to Figures 1,2,3,4 and Table 1 presented in this study is
available with the online version of this article.
Additional data file 1 All ICAT protein quantifications and statistical analyses pertaining  to Figures 1,2,3,4 and Table 1 presented in this study All ICAT protein quantifications and statistical analyses pertaining  to Figures 1,2,3,4 and Table 1 presented in this study Click here for additional data file
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